Yahoo · Oct 9, 2026
Biohaven partners with Ono in $100m IgG degrader deal
The transaction grants Ono exclusive rights for candidates BHV-1300, BHV-1310, and BHV-1320 across Taiwan, South Korea, and Japan.
NYSE · BHVN
Biohaven Ltd.
Healthcare · Biotechnology
$10.93
Down-$0.49 (-4.29%)
Updated Oct 15, 2026, 11:33 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.21B
- P/E ratio
- -1.55
- Dividend yield
- 0.00%
- 52-week range
- $8.03 – $18.24
- Volume
- 1.78M
- Avg. volume
- 3.75M
Price performance · BHVN
BHVN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 14, 2026
BHVN closed at $10.93 after 21 trading sessions, down 9.07% for the selected period.
- Last close
- $10.93
- Period change
- -9.07%
- Period low
- $10.93
- Period high
- $14.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 14, 2026 | $11.39 | $11.50 | $10.82 | $10.93 | 1.78M |
| Oct 13, 2026 | $11.79 | $11.79 | $11.16 | $11.42 | 2.43M |
| Oct 12, 2026 | $11.91 | $11.99 | $11.65 | $11.81 | 1.62M |
| Oct 9, 2026 | $11.90 | $12.27 | $11.745 | $12.08 | 1.37M |
| Oct 8, 2026 | $11.83 | $12.12 | $11.46 | $11.93 | 2.7M |
| Oct 7, 2026 | $11.86 | $12.2318 | $11.845 | $11.88 | 2.15M |
| Oct 6, 2026 | $13.00 | $13.04 | $11.88 | $12.08 | 3.05M |
| Oct 5, 2026 | $12.85 | $13.31 | $12.45 | $12.97 | 1.67M |
| Oct 2, 2026 | $13.41 | $13.51 | $12.63 | $12.87 | 1.74M |
| Oct 1, 2026 | $13.31 | $13.62 | $13.035 | $13.14 | 1.51M |
| Sep 30, 2026 | $13.50 | $13.625 | $13.21 | $13.35 | 1.43M |
| Sep 29, 2026 | $13.12 | $13.50 | $12.93 | $13.29 | 1.53M |
| Sep 28, 2026 | $12.82 | $13.4193 | $12.49 | $13.27 | 2.05M |
| Sep 25, 2026 | $13.25 | $13.35 | $12.77 | $12.99 | 1.58M |
| Sep 24, 2026 | $13.43 | $13.6299 | $12.76 | $13.19 | 3.03M |
| Sep 23, 2026 | $14.84 | $14.84 | $13.51 | $13.67 | 2.74M |
| Sep 22, 2026 | $14.42 | $14.97 | $14.22 | $14.85 | 2.43M |
| Sep 21, 2026 | $13.90 | $14.49 | $13.555 | $14.22 | 3.29M |
| Sep 18, 2026 | $14.07 | $14.37 | $13.46 | $13.62 | 6.43M |
| Sep 17, 2026 | $12.18 | $14.325 | $12.05 | $13.89 | 5.83M |
| Sep 16, 2026 | $12.34 | $12.44 | $11.93 | $12.02 | 2.25M |
Latest BHVN news
The latest Smart Investors Daily articles mentioning BHVN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BHVN research
Overview
Company profile and research snapshot.
Company profile
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $22.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HC Wainwright & Co. | Neutral | — |
| Sep 8, 2026 | RBC Capital | Sector Perform | — |
| Aug 12, 2026 | Morgan Stanley | Overweight | — |
| Aug 11, 2026 | RBC Capital | Outperform | — |
| Jun 29, 2026 | B of A Securities | Underperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 8, 2026
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
Biohaven signs a $100 million Asian licensing agreement with Ono Pharmaceutical for its Phase 3 MoDE pan IgG degrader portfolio.
Yahoo · Oct 8, 2026
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
Biohaven Ltd. together with its wholly owned subsidiaries, ("Biohaven") (NYSE: BHVN) today announced that it has entered into a strategic licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. ("Ono") (TYO: 4528), under which Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE™ pan IgG degrader portfolio, led by BHV-1300 and including next-generation follow-on degraders BHV-1310 and BHV-1320, in Japan, South Korea, Taiwan, and the countries of the A
Yahoo · Oct 8, 2026
Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?
In September 2026, Biohaven Ltd. announced a clinical supply agreement with Regeneron Pharmaceuticals to test BHV-1530 in combination with cemiplimab (Libtayo) in patients with solid tumors, following earlier monotherapy and preclinical data suggesting potential synergy with Anti-PD-1 therapy. This new BHV-1530 collaboration builds on an existing supply agreement for Biohaven’s next-generation TROP2-directed ADC BHV-1510, deepening Regeneron’s involvement across Biohaven’s oncology...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
